A pilot efficacy and tolerability trial of memantine for essential tremor

Clinical Neuropharmacology

Volumn 33, Issue 5, 2010, Pages 223-226

  Handforth, Adrian ^a   Bordelon, Yvette ^b   Frucht, Steven J ^c   Quesada, Arnulfo ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

clinical trial; essential tremor; memantine

Indexed keywords

MEMANTINE; PLACEBO;

ACCELEROMETRY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL TREMOR; FEMALE; HUMAN; HYPERTENSION; MALAISE; MALE; MONOTHERAPY; NEUROTRANSMISSION; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WASHINGTON HEIGHTS INWOOD GENETIC ESSENTIAL TREMOR RATING SCALE; WEIGHT GAIN;

AGED; DISABILITY EVALUATION; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MEMANTINE; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 77958017632     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181ebd109     Document Type: Article

References (27)

1. Hallett M, Dubinsky RM. Glucose metabolism in the brain of patients with essential tremor. J Neurol Sci 1993;114:45Y48.
2. Jenkins IH, Bain PG, Colebatch JG, et al. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol 1993;34:82Y90.
3. Málly J, Baranyi M, Vizi ES. Change in the concentrations of amino acids in CSF and serum of patients with essential tremor. J Neural Transm 1996;103:555Y560.
4. Petralia RS, Yokotani N, Wenthold RJ. Light and electron microscope distribution of the NMDA receptor subunit NMDAR1 in the rat nervous system using a selective anti-peptide antibody. J Neurosci 1994;14: 667Y696.
5. Chen L-W, Tse YC, Li C, et al. Differential expression of NMDA and AMPA/KA receptor subunits in the inferior olive of postnatal rats. Brain Res 2006;1067:103Y114.
6. de Montigny C, Lamarre Y. Rhythmic activity induced by harmaline in the olivo-cerebello-bulbar system of the cat. Brain Res 1973;53:81Y95.
7. Beitz AJ, Saxon D. Harmaline-induced climbing fiber activation causes amino acid and peptide release in the rodent cerebellar cortex and a unique temporal pattern of Fos expression in the olivo-cerebellar pathway. J Neurocytol 2004;33:49Y74.
8. Yang G, Iadecola C. Activation of cerebellar climbing fibers increases cerebellar blood flow: role of glutamate receptors, nitric oxide, and cGMP. Stroke 1998;29:499Y507.
9. Du W, Harvey JA. Harmaline-induced tremor and impairment of learning are both blocked by dizocilpine in the rabbit. Brain Res 1997;745:183Y188.
10. Wood PL, Richard JW, Pilapil C, et al. Antagonists of excitatory amino acids and cyclic guanosine monophosphate in cerebellum. Neuropharmacology 1982;21:1235Y1238.
11. Eblen F, Löschmann PA, Wudie;llner U, et al. Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartateYinduced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions. Eur J Pharmacol 1996;299:9Y16.
12. Paterson NE, Malekiani SA, Foreman MM, et al. Pharmacological characterization of harmaline-induced tremor activity in mice. Eur J Pharmacol 2009;616:73Y80.
13. Möbius HJ, Stö ffler A, Graham SM. Memantine hydrochloride: pharmacological and clinical profile. Drugs Today (Barc) 2004;40: 685Y695.
14. Starck M, Albrecht H, Pöllmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1997;244:9Y16.
15. Schneider E, Fischer PA, Clemens R, et al. Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study. Dtsch Med Wochenschr 1984;109:987Y990.
16. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2 High receptors. Synapse 2008;62:149Y153.
17. Peeters M, Romieu P, Maurice T, et al. Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004;19:2212Y2220.
18. Onogi H, Ishigaki S, Nakagawasai O, et al. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol Pharm Bull 2009;32:850Y855.
19. Findley LJ, Koller WC. Definitions and behavioral classifications. In: Findley LJ, Koller WC, eds. Handbook of Tremor Disorders. New York: Marcel Dekker; 1995:1Y5.
20. Louis ED, Barnes L, Wendt KJ, et al. A teaching videotape for the assessment of essential tremor. Mov Disord 2001;16:89Y93.
21. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004;19:1215Y1221.
22. Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999;56:475Y480.
23. Fahn SE, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 2nd ed. Baltimore, MD: Williams & Wilkins; 1993:271Y280.
24. Jankovic J, Schwartz K, ClemenceW, et al. A randomized, double-blind, placebo controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996;11:250Y256.
25. Handforth A, Martin FC, Kang GA, et al. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009;24:437Y440.
26. Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005;65:1967Y1969.
27. Louis ED. Essential tremors: a family of neurodegenerative disorders? Arch Neurol 2009;66:1202Y1208.